Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis

…, G Schnapp, KE Hostettler, S Stowasser… - European …, 2015 - Eur Respiratory Soc
Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal disease characterised
by fibrosis of the lung parenchyma and loss of lung function. Although the pathogenic …

Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review

…, VC Amatto, J Behr, S Stowasser - European Respiratory …, 2015 - Eur Respiratory Soc
Idiopathic pulmonary fibrosis (IPF) is associated with a fatal prognosis and manifests in
patients over 60 years old who may have comorbidities. The prevalence and impact of …

Fibrosing interstitial lung diseases: knowns and unknowns

…, M Quaresma, S Stowasser, S Harari - European …, 2019 - Eur Respiratory Soc
Patients with certain types of fibrosing interstitial lung disease (ILD) are at risk of developing
a progressive phenotype characterised by self-sustaining fibrosis, decline in lung function, …

[HTML][HTML] Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

…, F Le Maulf, M Girard, S Stowasser… - … England Journal of …, 2014 - Mass Medical Soc
Background Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that
targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of …

[HTML][HTML] Nintedanib in progressive fibrosing interstitial lung diseases

…, M Kolb, K Tetzlaff, S Stowasser… - … England Journal of …, 2019 - Mass Medical Soc
Background Preclinical data have suggested that nintedanib, an intracellular inhibitor of
tyrosine kinases, inhibits processes involved in the progression of lung fibrosis. Although the …

[HTML][HTML] Nintedanib for systemic sclerosis–associated interstitial lung disease

…, M Alves, E Clerisme-Beaty, S Stowasser… - … England Journal of …, 2019 - Mass Medical Soc
… Patients who had systemic sclerosis with an onset of the first non-Raynaud’s symptom
within the past 7 years and a high-resolution computed tomographic scan that showed fibrosis …

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised …

…, B Crestani, WA Wuyts, S Stowasser… - The lancet Respiratory …, 2020 - thelancet.com
Background The INBUILD trial investigated the efficacy and safety of nintedanib versus
placebo in patients with progressive fibrosing interstitial lung diseases (ILDs) other than …

[HTML][HTML] Trial of a preferential phosphodiesterase 4B inhibitor for idiopathic pulmonary fibrosis

…, V Cottin, C Hesslinger, S Stowasser… - … England Journal of …, 2022 - Mass Medical Soc
Background Phosphodiesterase 4 (PDE4) inhibition is associated with antiinflammatory and
antifibrotic effects that may be beneficial in patients with idiopathic pulmonary fibrosis. …

[HTML][HTML] Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS® trials

…, Z Bailes, R Schlenker-Herceg, S Stowasser… - Respiratory …, 2016 - Elsevier
Background and purpose The Phase II TOMORROW trial and two Phase III INPULSIS ® trials
investigated the efficacy and safety of nintedanib versus placebo in patients with idiopathic …

Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis. Results of the INJOURNEY trial

…, W Stansen, M Quaresma, S Stowasser… - American journal of …, 2018 - atsjournals.org
… No cases of Hy’s law were observed. Cases of Hy’s law were defined as AST or ALT at least
three times the ULN, total bilirubin at least twice the ULN measured in the same blood draw …